What is the diagnosis and management of Enterococcus faecalis infection?

Diagnosis and Management of Enterococcus faecalis Infection

Diagnosis

Blood cultures remain the cornerstone of diagnosis, with E. faecalis bacteremia requiring immediate echocardiographic evaluation regardless of acquisition source or portal of entry 1. The traditional modified Duke criteria underperform for enterococcal infections, with sensitivity of only 70% for definite endocarditis 1.

Key Diagnostic Considerations:

• Echocardiography is mandatory: Both transthoracic (TTE) and transesophageal echocardiography (TEE) should be performed when E. faecalis bacteremia is detected 2
• High suspicion for endocarditis: E. faecalis should be considered a "typical" endocarditis pathogen like S. aureus or viridans streptococci, improving diagnostic sensitivity to 96% 1
• Red flags for infective endocarditis include: prolonged symptom duration, growth in all blood culture bottles, unknown infection origin, heart murmur, and predisposition factors 3
• Recurrent bacteremia: Multiple episodes with E. faecalis are typically true relapses with identical isolates, strongly suggesting undiagnosed endocarditis 3

Essential Laboratory Testing:

All E. faecalis isolates must be tested for 4:

• Penicillin/ampicillin susceptibility (MIC determination)
• Vancomycin susceptibility (MIC determination)
• High-level gentamicin resistance (to predict synergistic activity)
• For resistant strains: daptomycin and linezolid susceptibility

Management

First-Line Treatment for Susceptible Strains

For penicillin-susceptible, aminoglycoside-susceptible E. faecalis, ampicillin plus ceftriaxone is the preferred regimen due to superior safety profile compared to aminoglycoside-containing regimens 4.

Preferred Regimen (Aminoglycoside-Susceptible):

• Ampicillin 2g IV every 4 hours PLUS Ceftriaxone 2g IV every 12 hours 4
• Duration: 6 weeks for all cases (native valve endocarditis, prosthetic valve endocarditis) 4
• Advantages: No nephrotoxicity, no need for drug level monitoring 4

Alternative Regimen (If Aminoglycoside-Susceptible):

• Ampicillin 2g IV every 4 hours (or Penicillin G 18-30 million units/24h continuous infusion) PLUS Gentamicin 1mg/kg IV every 8 hours 4
• Duration:
  • Native valve: 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months 4
  • Prosthetic valve: 6 weeks minimum 4
• Gentamicin dosing: Target 1-hour peak ~3 μg/mL, trough <1 μg/mL 4
• Critical caveat: Avoid in creatinine clearance <50 mL/min; use ampicillin-ceftriaxone instead 4

Aminoglycoside-Resistant Strains

For high-level aminoglycoside resistance (increasingly common at 26-50% of isolates), ampicillin-ceftriaxone is the only effective synergistic combination 4:

• Ampicillin 2g IV every 4 hours PLUS Ceftriaxone 2g IV every 12 hours for 6 weeks 4
• This regimen demonstrates similar cure rates with significantly fewer adverse events compared to aminoglycoside regimens 4

Penicillin-Allergic or β-Lactam Intolerant Patients

Vancomycin plus gentamicin is reasonable but inferior to β-lactam combinations 4:

• Vancomycin (dosed to trough 10-15 μg/mL) PLUS Gentamicin 1mg/kg IV every 8 hours
• Duration: 6 weeks for both native and prosthetic valve endocarditis 4
• Warning: Higher nephrotoxicity and ototoxicity risk; combination vancomycin-gentamicin should be avoided when possible 5, 4

Multidrug-Resistant E. faecalis (Vancomycin-Resistant)

For vancomycin-resistant strains, daptomycin at high doses (10-12 mg/kg/day) with combination therapy should be considered, though data are limited 4:

• Daptomycin 10-12 mg/kg IV every 24 hours (higher than FDA-approved 6 mg/kg) 4
• Consider adding: Ampicillin or ceftaroline for synergy, especially if daptomycin MIC is 3-4 μg/mL 4
• Alternative: Linezolid 600mg IV/PO every 12 hours for >6 weeks 4
  • Caution: Bacteriostatic only; risk of bone marrow suppression, neuropathy, drug interactions 4
• Mandatory: Infectious disease consultation, cardiology, and cardiac surgery involvement 4

Outpatient Parenteral Antimicrobial Therapy (OPAT)

For stable patients after initial hospitalization, a modified regimen of ampicillin 2g every 4 hours plus ceftriaxone 4g once daily can be safely administered at home 6:

• Requires programmable pump for ampicillin dosing
• Median home treatment duration: 22.5 days after initial hospital stabilization (median 25 days) 6
• Achieves clinical and microbiological cure with no recurrences 6

Oral Therapy Considerations

Oral therapy may be reasonable for selected stable patients after IV lead-in, though specific data for E. faecalis are limited 5:

• Patient must be clinically stable with cleared bacteremia
• No immediate need for surgery
• Adequate GI absorption expected
• Avoid: Sulfonamides, tetracyclines, macrolides (historically poor outcomes) 5

Critical Management Pitfalls

1. Inadequate initial evaluation: TEE is often not performed during first bacteremia episodes later diagnosed as endocarditis 3
2. Underestimating recurrence risk: Recurrent E. faecalis bacteremia represents relapse with identical strains, not reinfection 3
3. Aminoglycoside toxicity in elderly: Enterococcal IE patients are typically older with comorbidities and pre-existing renal dysfunction; gentamicin nephrotoxicity may exceed benefits 4
4. Inadequate treatment duration: Full 6-week courses are necessary for most cases, particularly with ampicillin-ceftriaxone 4
5. Daptomycin monotherapy for VRE: Insufficient data support monotherapy; combination therapy preferred 4

Resistance Trends

Global surveillance shows increasing resistance over time to chloramphenicol, fosfomycin, imipenem, linezolid, and tetracycline 7. Daptomycin and tigecycline maintain effectiveness globally 7. The proportion of E. faecium (more resistant) versus E. faecalis is increasing, potentially linked to piperacillin-tazobactam use 8.